Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel B Walter

Showing results (91-100 of 139) with videos related to

Pageof 14
Sort By:
Contemporary Clinical Trials Communications|October 29, 2021
A randomized, double-blind, placebo-controlled clinical trial of fluconazole as early empiric treatment of coccidioidomycosis pneumonia (Valley Fever) in adults presenting with community-acquired pneumonia in endemic areas (FLEET-Valley Fever)Julia A Messina, Eileen K Maziarz, John Galgiani, et al.
JAMA|May 6, 2014
Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trialFlor M Munoz, Nanette H Bond, Maurizio Maccato, et al.
Vaccine|December 15, 2015
Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccineInnocent N Mbawuike, Robert L Atmar, Shital M Patel, et al.
The Journal of Infectious Diseases|March 6, 2022
Gastrointestinal Microbiome Disruption and Antibiotic-Associated Diarrhea in Children Receiving Antibiotic Therapy for Community-Acquired PneumoniaJiye Kwon, Yong Kong, Martina Wade, et al.
Mbio|October 31, 2022
Infant Antibody Repertoires during the First Two Years of Influenza VaccinationMasayuki Kuraoka, Nicholas C Curtis, Akiko Watanabe, et al.
Vaccine|January 22, 2019
An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adultsChristopher W Woods, Ana M Sanchez, Geeta K Swamy, et al.
JAMA Pediatrics|January 6, 2025
Apnea After 2-Month Vaccinations in Hospitalized Preterm Infants: A Randomized Clinical TrialRachel G Greenberg, Wes Rountree, Mary Allen Staat, et al.
The Journal of Infectious Diseases|February 7, 2024
Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 VaccineXintao Hu, Krithika P Karthigeyan, Savannah Herbek, et al.
Vaccine|December 17, 2023
Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adultsLisa A Jackson, Jack T Stapleton, Emmanuel B Walter, et al.
JAMA|October 8, 2014
Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trialRobert B Belshe, Sharon E Frey, Irene L Graham, et al.
Pageof 14

Showing results (91-100 of 139) with videos related to

Sort By:
Pageof 14
Contemporary Clinical Trials Communications|October 29, 2021
A randomized, double-blind, placebo-controlled clinical trial of fluconazole as early empiric treatment of coccidioidomycosis pneumonia (Valley Fever) in adults presenting with community-acquired pneumonia in endemic areas (FLEET-Valley Fever)Julia A Messina, Eileen K Maziarz, John Galgiani, et al.
JAMA|May 6, 2014
Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trialFlor M Munoz, Nanette H Bond, Maurizio Maccato, et al.
Vaccine|December 15, 2015
Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccineInnocent N Mbawuike, Robert L Atmar, Shital M Patel, et al.
The Journal of Infectious Diseases|March 6, 2022
Gastrointestinal Microbiome Disruption and Antibiotic-Associated Diarrhea in Children Receiving Antibiotic Therapy for Community-Acquired PneumoniaJiye Kwon, Yong Kong, Martina Wade, et al.
Mbio|October 31, 2022
Infant Antibody Repertoires during the First Two Years of Influenza VaccinationMasayuki Kuraoka, Nicholas C Curtis, Akiko Watanabe, et al.
Vaccine|January 22, 2019
An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adultsChristopher W Woods, Ana M Sanchez, Geeta K Swamy, et al.
JAMA Pediatrics|January 6, 2025
Apnea After 2-Month Vaccinations in Hospitalized Preterm Infants: A Randomized Clinical TrialRachel G Greenberg, Wes Rountree, Mary Allen Staat, et al.
The Journal of Infectious Diseases|February 7, 2024
Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 VaccineXintao Hu, Krithika P Karthigeyan, Savannah Herbek, et al.
Vaccine|December 17, 2023
Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adultsLisa A Jackson, Jack T Stapleton, Emmanuel B Walter, et al.
JAMA|October 8, 2014
Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trialRobert B Belshe, Sharon E Frey, Irene L Graham, et al.
Pageof 14